HOXA9 and glioblastoma: Globally, both assays revealed that all HOXA9-high cell lines hTERT/E6/E7, U87MG, U251, and GBML18 (red lines) presented higher cell viability in basal conditions than their respective HOXA9-low counterparts (blue lines; Figure 6C–6F and Supplementary Figure 11A–11D), and that temozolomide-mediated cytotoxicity was significantly more pronounced in HOXA9-low cells than in HOXA9-high cells (Figure 6C–6F and Supplementary Figure 11A–11D), collectively indicating that HOXA9 contributes to temozolomide resistance in GBM cells.